Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Aptinyx Inc (APTX)

Aptinyx Inc (APTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 35,903
  • Shares Outstanding, K 67,716
  • Annual Sales, $ 1,000 K
  • Annual Income, $ -74,890 K
  • 60-Month Beta 1.28
  • Price/Sales 37.24
  • Price/Cash Flow N/A
  • Price/Book 0.48
Trade APTX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.89
  • Most Recent Earnings -0.29 on 05/12/22
  • Next Earnings Date 08/09/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 337.88% ( +26.61%)
  • Historical Volatility 84.48%
  • IV Percentile 87%
  • IV Rank 23.93%
  • IV High 1,174.48% on 06/07/22
  • IV Low 74.72% on 10/19/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 13
  • Volume Avg (30-Day) 7
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 1,181
  • Open Int (30-Day) 1,124

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.29
  • Number of Estimates 5
  • High Estimate -0.26
  • Low Estimate -0.30
  • Prior Year -0.29
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3600 +60.00%
on 06/14/22
0.6097 -5.53%
on 07/01/22
+0.1497 (+35.12%)
since 06/06/22
3-Month
0.3600 +60.00%
on 06/14/22
1.4600 -60.55%
on 04/07/22
-1.7640 (-75.38%)
since 04/06/22
52-Week
0.3600 +60.00%
on 06/14/22
3.7599 -84.68%
on 02/17/22
-2.2640 (-79.72%)
since 07/06/21

Most Recent Stories

More News
Aptinyx to Participate in H.C. Wainwright 1st Annual Mental Health Conference

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present...

APTX : 0.5780 (+9.02%)
Aptinyx to Participate in H.C. Wainwright Global Investment Conference

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced that company management will present...

APTX : 0.5780 (+9.02%)
Aptinyx Announces Poster Presentation Highlighting Preclinical Data on NYX-783 in Models of PTSD at the 2022 American Psychiatric Association Annual Meeting

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical...

APTX : 0.5780 (+9.02%)
Aptinyx Inc. (APTX) Q1 2022 Earnings Call Transcript

APTX earnings call for the period ending March 31, 2022.

APTX : 0.5780 (+9.02%)
Aptinyx Reports First Quarter 2022 Financial Results and Highlights Recent Clinical Progress

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first...

APTX : 0.5780 (+9.02%)
Teladoc (TDOC) Plunges 40.3% Since Q1 Earnings Beat: Here's Why

Teladoc Health's (TDOC) bet on mental health service BetterHelp is likely to generate lower yield this year.

ANGN : 1.1300 (+0.89%)
TDOC : 38.81 (-0.45%)
ASND : 89.51 (-6.16%)
APTX : 0.5780 (+9.02%)
Aptinyx Presents Preclinical Data on NYX-783 in Models of PTSD at 2022 Society of Biological Psychiatry Annual Meeting

Aptinyx Inc. (NASDAQ: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today presented data from preclinical...

APTX : 0.5780 (+9.02%)
Aptinyx to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will...

APTX : 0.5780 (+9.02%)
Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear with NYX-783

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that data from preclinical...

APTX : 0.5780 (+9.02%)
Aptinyx (APTX) Tanks as Neuropathic Pain Study Misses Goal

Aptinyx's (APTX) phase IIb study evaluating the effects of NYX-2925 in patients with painful diabetic peripheral neuropathy misses the primary endpoint. Stock falls sharply.

VYGR : 6.17 (-3.89%)
APTX : 0.5780 (+9.02%)
APLT : 0.9265 (+4.10%)
GRTX : 1.3300 (+1.53%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel, proprietary and synthetic small molecules for the treatment of brain and nervous system disorders. The company's product pipeline consists of NYX-2925, NYX-783 and NYX-458 which are in...

See More

Key Turning Points

3rd Resistance Point 0.6701
2nd Resistance Point 0.6201
1st Resistance Point 0.5751
Last Price 0.5780
1st Support Level 0.4801
2nd Support Level 0.4301
3rd Support Level 0.3851

See More

52-Week High 3.7599
Fibonacci 61.8% 2.4611
Fibonacci 50% 2.0600
Fibonacci 38.2% 1.6588
Last Price 0.5780
52-Week Low 0.3600

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar